Where do the receptor head and tails come from?

• Head from signaling chains, tails from antibodies
• Head from antibody binding regions, tails from signaling chains
• Both parts from viral coat proteins

What path does engineered T-cell manufacture follow?

• Cells out, gene inserted by vector, product checked, cells returned
• Gene injected directly into the tumour
• Donor cells given with no modification

Poor cell expansion during manufacture is only a logistics problem, not a treatment failure.

Why have solid tumours proved harder targets than B-cell cancers?

• They lack a uniform flag like CD19
• Their cells cannot be collected
• Viral vectors cannot enter solid tissue

Swapping the signaling tails changes the therapy. What does it change?

• Whether a vector is needed
• Which marker the cell finds
• How hard the cell fires and how long it survives

Healthy B cells die alongside the tumour during therapy. Why?

• The vector infected them by mistake
• They carry the same marker the receptor head aims at
• The returned cells attack at random

A proposal aims the receptor at a marker shared with vital healthy tissue. What is your verdict?

• Reject the target choice: severe off-tumour hitting is predictable
• Approve it for solid tumours only
• Approve it, since firing can be tuned later

You strengthen the signaling tails for a hotter response. What toxicity should you predict?

• Loss of the antibody head
• Weaker engraftment of the cells
• A greater storm of released cytokines